Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

23.00 -0.49 (-2.09%)
Streaming Delayed Price Updated: 2:12 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
News headline image
Earnings Preview: Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today ↗
These three biotech stocks were on the volatile side today. 
Via The Motley Fool
News headline image
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma ↗
The company is working on a treatment for the eye disease known as geographic atrophy. 
Via Investor's Business Daily
News headline image
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Wedbush Maintains Neutral Rating for Apellis Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
9 Analysts Have This to Say About Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Why Apellis Pharmaceuticals Stock Is Soaring Today ↗
Rare disease-focused Apellis Pharmaceuticals Inc (NASDAQ: APLS) is reportedly drawing takeover interest from large drugmakers. 
Via Benzinga
News headline image
Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Best Growth Stocks to Buy in April ↗
Takeover interest is spurring these two biotech stocks higher. 
Via The Motley Fool
News headline image
Apellis Pharmaceuticals's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) Making Surprising Moves in Monday Session
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals, VirTra And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Wall Street Upgraded This Stock's Price Target After a New Approval: Is It a Buy? ↗
The company's lead therapy was just approved for another indication. 
Via The Motley Fool
News headline image
Why Apellis Pharmaceuticals Stock Surged This Week ↗
A highly eventful five days for the company saw bulls pile into its shares. 
Via The Motley Fool
News headline image
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.